58.80
2.69 (4.79%)
| Previous Close | 56.11 |
| Open | 55.79 |
| Volume | 993,851 |
| Avg. Volume (3M) | 1,053,539 |
| Market Cap | 4,858,308,096 |
| Price / Sales | 5.22 |
| Price / Book | 4.53 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CG Oncology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 2,221,474 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 36.05%) | Buy |
| Median | 73.00 (24.15%) | |
| Low | 70.00 (Piper Sandler, 19.05%) | Buy |
| 70.00 (Wedbush, 19.05%) | Buy | |
| Average | 73.60 (25.17%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 53.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 80.00 (36.05%) | Buy | 58.80 |
| Truist Securities | 10 Feb 2026 | 75.00 (27.55%) | Buy | 53.09 |
| 12 Jan 2026 | 66.00 (12.24%) | Buy | 53.72 | |
| RBC Capital | 21 Jan 2026 | 73.00 (24.15%) | Buy | 57.13 |
| Piper Sandler | 16 Jan 2026 | 70.00 (19.05%) | Buy | 54.73 |
| Wedbush | 11 Dec 2025 | 70.00 (19.05%) | Buy | 41.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jan 2026 | Announcement | CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC |
| 06 Jan 2026 | Announcement | CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 18 Dec 2025 | Announcement | SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award |
| 05 Dec 2025 | Announcement | New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |